Pacira BioSciences Inc
For the period ended Sep 30, 2024. Filed Nov 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 6, 2024
PCRX$36.49+0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities: | ||
| Net (loss) income | $(115,601) | $17,085 |
| Adjustments to reconcile net (loss) income to net cash provided by operating activities: | ||
| Goodwill impairment | 163,243 | — |
| Deferred taxes | 17,113 | 9,014 |
| Depreciation of fixed assets and amortization of intangible assets | 57,542 | 57,089 |
| Amortization of debt issuance costs | 2,284 | 2,311 |
| Amortization of debt discount | 70 | 728 |
| (Gain) loss on early extinguishment of debt | (7,518) | 16,926 |
| Stock-based compensation | 38,905 | 35,475 |
| Changes in contingent consideration | (5,541) | (3,847) |
| Other net (gains) losses | (53) | 2,415 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | 4,903 | 1,440 |
| Inventories, net | (7,512) | (457) |
| Prepaid expenses and other assets | (6,338) | (6,986) |
| Accounts payable | 3,409 | 1,988 |
| Accrued expenses and income taxes payable | 12,546 | (26,156) |
| Other liabilities | (1,195) | 40 |
| Net cash provided by operating activities | 156,257 | 107,065 |
| Investing activities: | ||
| Purchases of fixed assets | (8,518) | (13,363) |
| Purchases of available-for-sale investments | (207,017) | (111,682) |
| Sales of available-for-sale investments | 132,627 | 200,970 |
| Purchases of debt investments | — | (6,758) |
| Net cash (used in) provided by investing activities | (82,908) | 69,167 |
| Financing activities: | ||
| Proceeds from exercises of stock options | — | 1,939 |
| Proceeds from shares issued under employee stock purchase plan | 1,364 | 1,672 |
| Payment of employee withholding taxes on restricted stock unit vests | (414) | — |
| Purchase of treasury stock | (25,000) | — |
| Proceeds from 2029 convertible senior notes | 287,500 | — |
| Proceeds from Term loan A facility | — | 149,550 |
| Repayment of 2024 convertible senior notes | (8,641) | — |
| Repayment of 2025 convertible senior notes | (190,994) | — |
| Repayment of Term loan B facility | — | (296,875) |
| Repayment of Term loan A facility | (8,438) | (30,625) |
| Purchase of capped call transactions | (26,709) | — |
| Debt extinguishment costs | — | (5,750) |
| Payment of debt issuance and financing costs | (9,350) | (1,163) |
| Net cash provided by (used in) financing activities | 19,318 | (181,252) |
| Net increase (decrease) in cash and cash equivalents | 92,667 | (5,020) |
| Cash and cash equivalents, beginning of period | 153,298 | 104,139 |
| Cash and cash equivalents, end of period | $245,965 | $99,119 |
| See accompanying condensed notes to consolidated financial statements. | ||
| PACIRA BIOSCIENCES, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED) (In thousands)(Unaudited) | ||
|---|---|---|
| Nine Months EndedSeptember 30, | ||
| 2024 | 2023 | |
| Supplemental cash flow information: | ||
| Cash paid for interest | $10,191 | $24,931 |
| Net cash paid for income taxes | $9,575 | $2,072 |
| Non-cash investing and financing activities: | ||
| Fixed assets included in accounts payable and accrued liabilities | $415 | $1,470 |
| Excise tax on share repurchases included in accrued liabilities | $121 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.